Neoadjuvant CD40 agonism in pancreatic cancer resulted in an increased density of DCs and a T cell–enriched tumor microenvironment compared to historical controls treated with chemotherapy, radiation, or no neoadjuvant therapy (7). This evidence concerns the gene CD40 and pancreatic neoplasm.